No Data
No Data
No Data
No Data
No Data
Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Cfb for Treatment of Complement Mediated Kidney Disease
Moomoo 24/707:33 ET
Express News | Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Moomoo 24/707:32 ET
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares May Have Run Too Fast Too Soon
With a price-to-sales (or "P/S") ratio of 15.2x Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) may be sending bearish signals at the moment, given that almost half of all Biotechs companies in the Unit
Simply Wall StApr 22 11:40 ET
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
Express News | Turnstone Biologics Appoints William Waddill to Its Board of Directors
Moomoo 24/7Apr 16 09:00 ET
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Seeking AlphaApr 10 12:03 ET
No Data
No Data